CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $59.07, moving -3.46% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.1%.
CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
CRISPR Therapeutics (SRSP) stock gains as the company gets a new Overweight rating from J.P. Morgan thanks to its therapeutic ...
Recent discussions on X about CRISPR Therapeutics (CRSP) have been buzzing with excitement following the company's stock hitting a 52-week high of $62.32 and news of a significant insider purchase by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback